Mesothelioma Clinical Trial Combines Immunotherapy Drugs

Dr. Tawee Tanvetyanon at the Moffitt Cancer Center in Tampa rarely sounds this enthused about the future prospects for patients with pleural mesothelioma. Finally, he has something promising to offer. Tanvetyanon is the principal investigator of a much-anticipated phase II clinical trial involving an immunotherapy drug combination with considerable potential for extending survival. “This is exciting. We now can offer something with realistic hope,” he told Asbestos.com. “We haven’t had anything like this for mesothelioma in a long time. I really look forward to speaking with these patients now.” Moffitt recently became the first multidisciplinary specialty center to begin enrolling mesothelioma patients in a trial that will evaluate the efficacy of combining CRS-207 with pembrolizumab — two immunotherapy drugs that already showed effectiveness individually — in a second-line setting. “Of course, the hope is that we see significant tumor shrinkage. We already know, we have data, that each of these agents will work in a number of patients,” Tanvetyanon said. “There is good reason to think that combining the two will work even better, a one-plus-one-equals-three synergy.” Drug Companies Working Together Two competing pharmaceutical companies have worked together to make this latest, anti-cancer combination a reality for mesothelioma patients. Aduro Biotech, based in Berkeley, California, produces CRS-207, which us...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Tags: Abramson Cancer Center Aduro Biotech CRS-207 Dr. Tawee Tanvetyanon FDA approval Keytruda improving mesothelioma prognosis Merck mesothelioma chemotherapy mesothelioma clinical trials mesothelioma immunotherapy moffitt cancer center m Source Type: news

Related Links:

A video of the very sweet moment a young Tennessee girl learned she was cancer-free has gone viral.
Source: ABC News: Health - Category: Consumer Health News Tags: Health Source Type: news
Authors: Emmanuel S, Jornayvaz FR Abstract Discovered 20 years ago, Fibroblast Growth Factor (FGF) 19, and its mouse ortholog FGF15, were the first members of a new subfamily of FGFs able to act as hormones. During fetal life, FGF15/19 is involved in organogenesis, affecting the development of the ear, eye, heart and brain. At adulthood, FGF15/19 is mainly produced by the ileum, acting on the liver to repress hepatic bile acid synthesis and promote postprandial nutrient partitioning. In rodents, pharmacologic doses of FGF19 induce the same anti-obesity and anti-diabetic actions as FGF21, these metabolic effects bei...
Source: Endocrine Reviews - Category: Endocrinology Tags: Endocr Rev Source Type: research
STEFAN KARL STEFANSSON, the LazyTown actor that starred as Robbie Rotten, has died after a battle with bile duct cancer. Bile duct cancer symptoms include  itchy skin and weight loss - these are the warning signs to look out for.
Source: Daily Express - Health - Category: Consumer Health News Source Type: news
Authors: Timmerman C, Taveras L, Huerta S Abstract INTRODUCTION: The standard of care for locally advanced rectal cancer includes neoadjuvant chemoradiation with subsequent total mesorectal excision. This approach has shown various degrees of response to neoadjuvant chemoradiation (ranging from complete response to further tumor growth), which have substantial prognostic and therapeutic implications. A total regression of the tumor is a predictor of superior oncologic outcomes compared to partial and non-responders. Further, this concept has opened the possibility of nonoperative strategies for complete responders ...
Source: Expert Review of Molecular Diagnostics - Category: Laboratory Medicine Tags: Expert Rev Mol Diagn Source Type: research
Conclusions: IAC is effective as primary therapy for unilateral group B, C, D, and E retinoblastoma. IvitC is an important adjuvant therapy to achieve comparable globe salvage rates for group D and E eyes with persistent active vitreous seeds.Ocul Oncol Pathol
Source: Ocular Oncology and Pathology - Category: Opthalmology Source Type: research
Authors: El-Chaer WK, Moraes CF, Nóbrega OT Abstract Although prostate cancer (PCa) is the sixth most common type of neoplasm in the world and the second in prevalence among men (10% of all cases), there is shortage of studies focused on primary prevention of the disorder as well as little understanding on its pathophysiology. Currently, the PCa screening tools are the prostate specific antigen (PSA) dosage conjugated to rectal examination and confirmed by prostate biopsy. Despite the name, the PSA presents reduced specificity, being necessary the identification of new biomarkers that allow an earlier and mo...
Source: Journal of Aging Research - Category: Geriatrics Tags: J Aging Res Source Type: research
In recent years, researchers working on forms of telomerase gene therapy have produced evidence to show that increased levels and activity of telomerase does not raise cancer risk in mice. The open access paper and publicity materials noted below report the latest example. Extra telomerase increases the sort of activities that are beneficial in the context of improved regenerative capacity, but might be thought to raise the risk of cancer when they take place in the damaged environment of old tissue. This means more stem cell activity, more cellular replication, and so forth. Somatic cells are limited in the degree ...
Source: Fight Aging! - Category: Research Authors: Tags: Medicine, Biotech, Research Source Type: blogs
SAN FRANCISCO - A California jury on Aug. 10 found that Monsanto Co. acted with malice regarding its failure to warn of the damages associated with glyphosate, the active ingredient in Roundup, and awarded $289,254,882.32 in damages in the bellwether case of a man who said his repeated exposure to the herbicide caused his cancer (DeWayne Johnson v. Monsanto Company, No. CGC 16550128, Calif. Super., San Francisco Co.).
Source: LexisNexis® Mealey's™ Emerging Toxic Torts Legal News - Category: Medical Law Source Type: news
SAN FRANCISCO - The California judge who presided over the trial in which a jury awarded $289 million to a man who said Monsanto Co. was liable for causing his cancer as a result of exposure to glyphosate confirmed Aug. 17 that the verdict was unanimous and that she was not expressing a vote when she polled the jury, as has been claimed by a Monsanto executive in an interview with the British Broadcasting Co. (BBC).
Source: LexisNexis® Mealey's™ Emerging Toxic Torts Legal News - Category: Medical Law Source Type: news
SAN FRANCISCO - The attorney representing a California man who contends that he developed cancer as a result of exposure to glyphosate on Aug. 7 presented closing arguments in the first trial related to the herbicide Roundup and asked a jury to "change the world" by holding Monsanto Co. accountable for its "reckless disregard for human health," which he said warranted an award of more than $412.25 million in combined damages (DeWayne Johnson v. Monsanto Company, No. CGC 16550128, Calif. Super., San Francisco Co.).
Source: LexisNexis® Mealey's™ Emerging Toxic Torts Legal News - Category: Medical Law Source Type: news
More News: Asbestosis | Biotechnology | Cancer | Cancer & Oncology | Cancer Therapy | Chemotherapy | Clinical Trials | Environmental Health | Genetics | Head and Neck Cancer | Immunotherapy | Listeria | Melanoma | Merck | Mesothelioma | Non-Small Cell Lung Cancer | Skin Cancer | Study